Papillomavirus E7 Proteins
"Papillomavirus E7 Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
ONCOGENE PROTEINS from papillomavirus that deregulate the CELL CYCLE of infected cells and lead to NEOPLASTIC CELL TRANSFORMATION. Papillomavirus E7 proteins have been shown to interact with various regulators of the cell cycle including RETINOBLASTOMA PROTEIN and certain cyclin-dependent kinase inhibitors.
| Descriptor ID |
D050725
|
| MeSH Number(s) |
D12.776.624.664.520.420
|
| Concept/Terms |
Papillomavirus E7 Proteins- Papillomavirus E7 Proteins
- E7 Proteins, Papillomavirus
- E7 Oncogene Proteins
- Oncogene Proteins, E7
- Oncogene Protein E7, Papillomavirus
|
Below are MeSH descriptors whose meaning is more general than "Papillomavirus E7 Proteins".
Below are MeSH descriptors whose meaning is more specific than "Papillomavirus E7 Proteins".
This graph shows the total number of publications written about "Papillomavirus E7 Proteins" by people in this website by year, and whether "Papillomavirus E7 Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Papillomavirus E7 Proteins" by people in Profiles.
-
Tsyn-Seq: a T-cell Synapse-Based Antigen Identification Platform. Cancer Immunol Res. 2024 May 02; 12(5):530-543.
-
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. Invest New Drugs. 2023 04; 41(2):284-295.
-
Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers. Clin Cancer Res. 2022 10 14; 28(20):4479-4493.
-
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
-
Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers. Genome Res. 2022 01; 32(1):55-70.
-
Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice. Cancer Sci. 2020 Oct; 111(10):3576-3587.
-
Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models. Int J Cancer. 2020 12 01; 147(11):3236-3249.
-
HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Invest. 2020 04 01; 130(4):1635-1652.
-
Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: Concurrent cohorts with a 5-year follow-up. Int J Cancer. 2020 06 01; 146(11):3114-3123.
-
Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. Cancer Res. 2018 11 01; 78(21):6159-6170.